Economics of Antimicrobial Resistance Fellowships
The O’Neill Review on antimicrobial resistance (AMR) estimated that by 2050 AMR would cost 2-3.5% GDP. A 2017 report by the World Bank further emphasised that the greatest economic impact would be felt in low income countries with an estimated 5.6% drop in GDP by 2050 in the event of high drug-resistance.
It is more important than ever to build capacity at a country level to link surveillance data on resistance and use to the economic problem posed by AMR.
This grant uses the existing Overseas Development Institute (ODI) economic fellowship model to place fellows in low- and middle-income countries’ (LMICs) One Health Ministries (or relevant institutes) that have expressed an interest in hosting a fellow for a minimum of two years. Fellows will be early career professionals who are either health economists or with a commitment to using economic skills for health policy.
The grant will support a total of 10 skilled health economists placed in LMIC agencies in 10 of the Fleming Fund priority countries.
Overseas Development Institute (ODI)
5 years (November 2018 - March 2023)
The purpose is to uplift and build the capacity of Fleming Fund partner countries in several core economic competencies that underpin the development of evidence-based policy relevant to addressing AMR. The project will aim to build capacity in:
- economic analysis of relevant data (including AMR and antimicrobial use (AMU) surveillance data)
- economic appraisal of policy options, including cost/benefit analyses
- research capacity in the review of regulations, incentives and opportunities that shape AMU
- gap analysis of public health data to provide a coherent demand side perspective on what data is required (in what format) to support economic analysis and policy development